Swiss National Bank Reduces Stock Position in Viridian Therapeutics, Inc. $VRDN

Swiss National Bank lowered its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 4.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 107,500 shares of the company’s stock after selling 5,100 shares during the period. Swiss National Bank owned about 0.13% of Viridian Therapeutics worth $1,449,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Amalgamated Bank grew its stake in shares of Viridian Therapeutics by 49.7% during the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock valued at $34,000 after purchasing an additional 840 shares during the period. Foresite Capital Management VI LLC bought a new position in shares of Viridian Therapeutics in the 4th quarter worth approximately $38,000. GAMMA Investing LLC boosted its holdings in shares of Viridian Therapeutics by 3,892.9% in the first quarter. GAMMA Investing LLC now owns 8,425 shares of the company’s stock worth $114,000 after buying an additional 8,214 shares during the last quarter. Dark Forest Capital Management LP bought a new stake in Viridian Therapeutics during the fourth quarter valued at approximately $255,000. Finally, Brevan Howard Capital Management LP bought a new stake in Viridian Therapeutics during the fourth quarter valued at approximately $258,000.

Wall Street Analyst Weigh In

Several research analysts have weighed in on VRDN shares. Needham & Company LLC decreased their price target on shares of Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. The Goldman Sachs Group upped their price objective on Viridian Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, August 7th. Royal Bank Of Canada decreased their target price on Viridian Therapeutics from $45.00 to $41.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. Wells Fargo & Company cut their price target on Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a report on Thursday, August 7th. Finally, Oppenheimer upped their price target on Viridian Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Thursday, August 7th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $37.00.

Viridian Therapeutics Stock Up 6.7%

VRDN opened at $19.23 on Monday. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -5.02 and a beta of 0.42. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.01 and a current ratio of 11.01. The firm’s fifty day moving average is $16.60 and its 200 day moving average is $15.09. Viridian Therapeutics, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.00). The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.Viridian Therapeutics’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.81) EPS. On average, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.